DE3679708D1 - Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen. - Google Patents

Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.

Info

Publication number
DE3679708D1
DE3679708D1 DE8686302781T DE3679708T DE3679708D1 DE 3679708 D1 DE3679708 D1 DE 3679708D1 DE 8686302781 T DE8686302781 T DE 8686302781T DE 3679708 T DE3679708 T DE 3679708T DE 3679708 D1 DE3679708 D1 DE 3679708D1
Authority
DE
Germany
Prior art keywords
specific
antigue
immunol
giving
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686302781T
Other languages
English (en)
Inventor
C Garrison Fathman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of DE3679708D1 publication Critical patent/DE3679708D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8686302781T 1985-04-17 1986-04-15 Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen. Expired - Lifetime DE3679708D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/724,063 US4681760A (en) 1985-04-17 1985-04-17 Method of conferring immunotolerance to a specific antigen

Publications (1)

Publication Number Publication Date
DE3679708D1 true DE3679708D1 (de) 1991-07-18

Family

ID=24908815

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686302781T Expired - Lifetime DE3679708D1 (de) 1985-04-17 1986-04-15 Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.

Country Status (6)

Country Link
US (1) US4681760A (de)
EP (1) EP0200412B1 (de)
JP (1) JP2530316B2 (de)
AT (1) ATE64304T1 (de)
CA (1) CA1266232A (de)
DE (1) DE3679708D1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
US7011834B1 (en) 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
CA1336818C (en) * 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5422258A (en) * 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
JPH03503164A (ja) * 1988-02-03 1991-07-18 エクソウマ　コーポレーション 抗‐パンｔ‐細胞イムノトキシン組成物による免疫抑制
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
EP0414816B1 (de) * 1988-05-19 1994-07-27 The Beth Israel Hospital Association Toleranzinduktion gegenüber einem fremdantigen
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
CA2015515C (en) * 1990-01-03 1999-12-07 Jean-Marie Saint-Remy Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
JPH05507851A (ja) * 1990-06-22 1993-11-11 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 免疫抑制抗―ｃｄ４―関連抗体を用いたモノクローナル抗体の改良された腹水生産
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993009141A1 (en) * 1991-11-01 1993-05-13 Joslin Diabetes Center Antigen associated with type i diabetes mellitus
JPH07508503A (ja) * 1992-02-27 1995-09-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・リランド・スタンフオード・ジユニア・ユニバーシテイ 自己免疫性糖尿病のための初期抗原（ｅａｒｌｙ　ａｎｔｉｇｅｎ）
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
US6696061B1 (en) 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
JPH08502244A (ja) * 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
JPH08332344A (ja) * 1995-06-09 1996-12-17 Honda Motor Co Ltd 内燃機関の排気浄化装置
DE69726674T2 (de) * 1996-04-10 2004-10-21 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EP1109570B1 (de) * 1998-08-31 2005-10-19 Biogen, Inc. Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
HUP0300421A2 (hu) * 2000-03-31 2003-06-28 Purdue Research Foundation Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20070172478A1 (en) * 2004-02-06 2007-07-26 Astellas Us Llc Methods of treating skin disorders
BRPI0510691A (pt) * 2004-05-04 2007-12-26 Genaissance Pharmaceuticals marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US8722343B2 (en) 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
KR20240095471A (ko) 2016-05-13 2024-06-25 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000938B1 (de) * 1977-08-22 1984-10-17 National Research Development Corporation Makromolekulare kovalente Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
WO1979000160A1 (en) * 1977-09-28 1979-04-05 Nat Res Dev Improvements in or relating to immunological preparations
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
DE3483996D1 (de) * 1983-09-15 1991-02-28 Univ Leland Stanford Junior Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells

Also Published As

Publication number Publication date
ATE64304T1 (de) 1991-06-15
EP0200412A2 (de) 1986-11-05
EP0200412A3 (en) 1988-03-30
JPS6236A (ja) 1987-01-06
CA1266232A (en) 1990-02-27
US4681760A (en) 1987-07-21
EP0200412B1 (de) 1991-06-12
JP2530316B2 (ja) 1996-09-04

Similar Documents

Publication Publication Date Title
DE3679708D1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DE3776041D1 (de) Teststreifen zur immunseparation.
PT86640A (pt) Hepatitis b virus surface antigens and hybrid antigens containing them
DE3854644D1 (de) Verfahren und Vorrichtungen zur Zellenbestimmung.
IT1195829B (it) Vaccini e saggi immunologici per l aids
PT87688A (pt) Hybrid protein c and method for its preparation
DK479083D0 (da) Materialer og metoder til herpes simplex-virus-vaccination
DE3679526D1 (de) Verfahren und vorrichtung fuer das ausrichten von einzelblaettern.
DE69005959D1 (de) Verfahren zur Reinigung von menschlichem Serum-Albumin.
IT1198289B (it) Antigene di flavvirus
AU1631188A (en) Newcastle disease virus vaccine and method for the application thereof
ATE3239T1 (de) Verfahren zum isolieren viraler glycoproteinischer antigene und deren verwendung fuer die bereitung von impfstoffen.
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
AU1308288A (en) Method to stimulate the immune response to specific antigens
KR890700683A (ko) 인체 면역 결핍 바이러스에 대한 항체 검색 방법
DK480589A (da) Immunanalysemetode
DE3674104D1 (de) Verfahren zur ausbildung von cuinse2-filmen.
DE68917138D1 (de) Toleranzinduktion gegenüber einem fremdantigen.
DE3750642D1 (de) Verfahren und Zusammensetzungen betreffend regressions-assoziierte Antigene.
DE3689174D1 (de) Verfahren zur Herstellung von Riboflavin.
DE3672327D1 (de) Verfahren und vorrichtung zur automatischen stapelung von elementen.
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
DE3784805D1 (de) Verfahren und vorrichtung zum gleichzeitigen einschieben von flachen gegenstaenden in ein albumblatt.
GB2114288B (en) Method for the detection of malaria antigens in human blood
DE3689206D1 (de) Verfahren zur Herstellung von deuterierter Acryl- oder Methacrylsäure.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee